Mark Gladwin

Dean of the University of Maryland School of Medicine · Univ of Maryland Sch of Med

Credentials: · · · · · ·

History

The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics
Review · Nature Reviews Drug Discovery · 2008 · Last of 3 authors · 2,053 citations
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program
Nature · 2021 · 1,859 citations
Sickle-cell disease
Review · The Lancet · 2010 · Last of 3 authors · 1,588 citations

Omics, Mice and Men: Development of Precision Transfusion Medicine
National Heart, Lung, and Blood Institute · R01
Contact PI · $12.5M · University of Maryland Baltimore
2009–2028
Airway Epithelial Cytoglobin Regulates Nitric Oxide Synthase and Development of Primary Ciliary Dyskinesia and Situs Inversus
National Heart, Lung, and Blood Institute · R01
Contact PI · $2.1M · University of Maryland Baltimore
2023–2027
Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin
National Heart, Lung, and Blood Institute · R01
Contact PI · $7.2M · University of Maryland Baltimore
2014–2027
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE
National Heart, Lung, and Blood Institute · UH3
Contact PI · $16.1M · University of Maryland Baltimore
2019–2027

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Principal investigator · Completed · Phase 2
Mark Gladwin
2017–2022
Storage Lesion in Banked Blood Due to Disruption of Nitric Oxide (NO) Homeostasis
Principal investigator · Completed · Phase 1
Mark Gladwin
2010–2013
Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease
Principal investigator · Terminated · Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2007–2009
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)
Study chair · Active not recruiting · Phase 3
University of Pittsburgh
2020–2026